One of the challenges inherent with managing HR+ early breast cancer—and HR+/HER2- cancer in particular—is the persistent risk of recurrence that extends over decades, with as much as 50% of recurrences occurring more than 5 years after diagnosis3. Here, ERBB2 is linked to breast cancer.